Testimony
Testimony for the House Energy and Commerce Subcommittee on Health (Prescription Drug Abuse and Diversion)
John M. Gray, President and CEO
April 7, 2014
Testimony for the House Energy and Commerce Subcommittee on Health (Pharmaceutical Traceability)
Elizabeth Gallenagh, Esq., Vice President, Government Affairs and General Counsel
April 25, 2013
Testimony for the Senate Commerce, Science and Transportation Committee (Drug Shortages)
John M. Gray, President and CEO
July 25, 2012
Testimony for the House Energy and Commerce Subcommittee on Health (Pharmaceutical Traceability)
Elizabeth Gallenagh, Esq., Vice President, Government Affairs and General Counsel
March 8, 2012
Testimony for the House Energy and Commerce Subcommittee on Commerce, Manufacturing, and Trade (Prescription Drug Abuse and Diversion)
John M. Gray, President and CEO
March 1, 2012
Testimony for the House Energy and Commerce Subcommittee on Health (Drug Shortages)
John M. Gray, President and CEO
September 23, 2011
Testimony for the U.S. Senate Health, Education, Labor and Pensions Committee (Drug Pricing)
Elizabeth Gallenagh, Esq., Senior Vice President, Government Affairs and General Counsel
October 17, 2017
Testimony for the Senate Committee on the Judiciary (The Ensuring Patient Access and Effective Drug Enforcement Act)
John M. Gray, President and CEO
December 12, 2017
Issues in Distribution
HDA reviews key priority issues and advocates on behalf of its pharmaceutical distributor members for standards, public policies and business processes that ensure a safe and efficient supply chain.
What is a Distributor?
Every day, primary pharmaceutical distributors sustain a complex supply chain, serving as a vital link in the healthcare system between manufacturers and healthcare providers. HDA's members work around the clock to help more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and other healthcare providers across the country keep their shelves stocked with the medications and products that patients need every day.